Browse > Article
http://dx.doi.org/10.3857/jkstro.2009.27.3.140

Survival Analysis of Patients with Brain Metastsis by Weighting According to the Primary Tumor Oncotype  

Gwak, Hee-Keun (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine)
Kim, Woo-Chul (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine)
Kim, Hun-Jung (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine)
Park, Jung-Hoon (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine)
Song, Chang-Hoon (Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine)
Publication Information
Radiation Oncology Journal / v.27, no.3, 2009 , pp. 140-144 More about this Journal
Abstract
Purpose: This study was performed to retrospectively analyze patient survival by weighting according to the primary tumor oncotype in 160 patients with brain metastasis and who underwent whole brain radiotherapy. Materials and Methods: A total of 160 metastatic brain cancer patients who were treated with whole brain radiotherapy of 30 Gy between 2002 and 2008 were retrospectively analyzed. The primary tumor oncotype of 20 patients was breast cancer, and that of 103 patients was lung cancer. Except for 18 patients with leptomeningeal seeding, a total of 142 patients were analyzed according to the prognostic factors and the Recursive Partitioning Analysis (RPA) class. Weighted Partitioning Analysis (WPA), with the weighting being done according to the primary tumor oncotype, was performed and the results were correlated with survival and then compared with the RPA Class. Results: The median survival of the patients in RPA Class I (8 patients) was 20.0 months, that for Class II (76 patients) was 10.0 months and that for Class III (58 patients) was 3.0 months (p<0.003). The median survival of patients in WPA Class I (3 patients) was 36 months, that for the patients in Class II (9 patients) was 23.7 months, that for the patients in Class III (70 patients) was 10.9 months and that for the patients in Class IV (60 patients) was 8.6 months (p<0.001). The WPA Class might have more accuracy in assessing survival, and it may be superior to the RPA Class for assessing survival. Conclusion: A new prognostic index, the WPA Class, has more prognostic value than the RPA Class for the treatment of patients with metastatic brain cancer. This WPA Class may be useful to guide the appropriate treatment of metastatic brain lesions.
Keywords
Brain metastasis; Whole brain radiotherapy; Prognostic index; Median survival;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-751   DOI   PUBMED   ScienceOn
2 Diener-West M, Dobbins TW, Phillips TL, Nelson DF. Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG Study 7916. Int J Radiat Oncol Biol Phys 1989;16:669-673   DOI   PUBMED   ScienceOn
3 Galicich JH, Sundaresan N, Arbit E, et al. Surgical treatment of single brain metastasis: factors associated with survival. Cancer 1980;45:381-386   DOI   ScienceOn
4 Winston KR, Walsh JW, Fischer EG. Results of operative treatment of intracranial metastatic tumors. Cancer 1980;45:2639-2645   DOI   ScienceOn
5 Schoggl A, Kitz K, Reddy M, et al. Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of single brain metastases. Acta Neurochir (Wien) 2000;142:621-626   DOI   ScienceOn
6 Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-2491   DOI   ScienceOn
7 Flickinger JC, Kondziolka D, Lunsford LD, et al. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994;28:797-802   DOI   PUBMED   ScienceOn
8 DeAngelis LM, Delattre JY, Posner JB. Radiationinduced dementia in patients cured of brain metastases. Neurology 1989;39:789-796   DOI   PUBMED
9 Regine WF, Huhn JL, Patchell RA, et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys 2002;52:333-338   DOI   PUBMED   ScienceOn
10 Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery or brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 1999;43:549-558   DOI   PUBMED   ScienceOn
11 O'Neill BP, Ituria NJ, Link MJ, Pollock BE, Ballman KV, O'Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 2003;55:1169-1176   DOI   PUBMED   ScienceOn
12 Weltman E, Salvajoli JV, Brandt RA, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 2000;46:1155-1161   DOI   PUBMED   ScienceOn
13 Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherpy alone or combined with neurosurgery? Ann Neurol 1993;33:583-590   DOI   ScienceOn
14 Sperduto PW, Berkey B, Gaspar L, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008;70:510-514   DOI   PUBMED   ScienceOn
15 Sause WT, Scott C, Krisch R, et al. Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. Int J Radiat Oncol Biol Phys 1993;26:653-657   DOI   PUBMED   ScienceOn
16 Asai A, Matsutani M, Kohno T, et al. Subacute brain atrophy after radiation therapy for malignant brain tumor. Cancer 1989;63:1962-1974   DOI   ScienceOn
17 Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007;68:1388-1395   DOI   PUBMED   ScienceOn
18 Sundaresan N, Galicich JH. Surgical treatment of brain metastases: clinical and computerized tomography evaluation of the results of treatment. Cancer 1985;55:1382-1388   DOI   ScienceOn
19 Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trail by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7:891-895   DOI   PUBMED   ScienceOn
20 Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500   DOI   PUBMED   ScienceOn
21 Regine WF, Scott C, Murray K, et al. Neurocognitive outcome in brain metastasis patients treated with accelerated fractionation vs accelerated hyperfractionation whole brain radiotherapy: an analysis from RTOG Study 91-04. Int J Radiat Oncol Biol Phys 2001;51:711-717   DOI   PUBMED   ScienceOn
22 Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980;6:1-9   DOI   PUBMED   ScienceOn
23 Pieper DR, Hess KR, Sawaya RE. Role of surgery in the treatment of brain metastses in patients with breast cancer. Ann Surg Oncol 1997;4:481-490   DOI   ScienceOn
24 Sneed PK, Suh JH, Goetsch SJ, et al. A multiinstitutional review of radiosurgery alone vs radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002;53:519-526   DOI   PUBMED   ScienceOn
25 White KT, Fleming TR, Laws ER Jr. Single metastasis to the brain.: surgical treatment in 122 consecutive patients. Mayo Clin Proc 1981;56:424-428   PUBMED
26 Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998;16:3563-3569   DOI   PUBMED
27 Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207-6219   DOI   ScienceOn